Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update

In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen, Qin, Chenman, Fei, Yunyun, Shen, Min, Zhou, Yangzhong, Zhang, Yan, Zeng, Xiaofeng, Zhang, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040414/
https://www.ncbi.nlm.nih.gov/pubmed/35477027
http://dx.doi.org/10.1016/j.clim.2022.109022
Descripción
Sumario:In March 2020, when coronavirus disease 2019 (COVID-19) was just beginning to spread around the world, we presented the potential benefits and controversies of anti-inflammatory therapy in COVID-19 patients based on the limited experience and proposed some types of anti-inflammatory drugs with potential therapeutic value, while without evidence-based data. In the past one more year, many clinical trials or real-world studies have been performed, either confirm or deny the efficacy of certain anti-inflammatory drugs in the treatment of COVID-19. In this review we summarize the progress of anti-inflammatory and immune therapy in COVID-19, including glucocorticoids, IL-6 antagonist, IL-1 inhibitor, kinase inhibitors, non-steroidal anti-inflammatory drugs and chloroquine/hydroxychloroquine.

Ejemplares similares